Teva-Handok Names Yoo Suk Hong as Chief Executive Officer

  Teva-Handok Names Yoo Suk Hong as Chief Executive Officer

  *Yoo Suk Hong, previous Lilly Korea CEO, recruited as first CEO of
  *Teva-Handok is scheduled to officially launch in September

Business Wire

JERUSALEM & SEOUL, South Korea -- April 8, 2013

Teva-Handok today announced the appointment of Yoo Suk Hong as the first Chief
Executive Officer of the business venture established between Teva
Pharmaceutical Industries Ltd. (NYSE: TEVA) and Handok Pharmaceuticals (KRX:
002390). This business venture was formed in February, 2013 and focuses on the
Korean pharmaceutical market, currently valued at approximately USD 14

“As we prepare to officially launch Teva-Handok, we are very pleased to
welcome Yoo Suk Hong as our CEO,” stated Prof. Itzhak Krinsky, Chairman of
Teva Japan, Chairman of Teva South Korea and Head of Business Development Asia
Pacific. “With his deep international experience coupled with his keen
understanding of the Korean market, Yoo Suk will help us realize our goal of
bringing high-quality and affordable medicines to patients in Korea.”

Handok Pharmaceutical’s Chairman and CEO Young Jin Kim stated, “CEO Yoo Suk
Hong has had a variety of work experiences in both Lilly headquarter and Korea
with remarkable achievements. I believe with his competencies developed
through global leadership, he will help establish Teva Handok as a leader in
the Korean market.”

Teva-Handok is expected to officially launch its first products in September

About Yoo Suk Hong

CEO Yoo Suk Hong graduated from Hankuk University of Foreign Studies and
received an MBA from the Wharton School of Business, University of
Pennsylvania. He worked as a financial analyst at Eli Lilly’s headquarters in
the US starting in 1992 and returned to Korea in 1995 first in new product
marketing and then as the head of marketing and sales. In 2003, Mr. Hong was
appointed as the global marketing manager of an osteoporosis medication at
Lilly’s US headquarters. He was appointed as the CEO of Lilly Korea in 2007
and then sent again to the headquarters in 2008 as the marketing strategy
director of emerging markets covering areas such as Korea, China, India,
Brazil and Russia.

About Teva-Handok

This business venture brings together Teva’s manufacturing expertise and
portfolio of generic and innovative medicines and Handok’s sales and
marketing, distribution, and regulatory affairs capabilities.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.

About HANDOK Pharmaceuticals

HANDOK, a leading innovation-driven pharmaceutical/healthcare company in
Korea, develops, manufactures and distributes healthcare solutions to improve
health and quality of life for all. Handok has a core business focus in
diabetes, cardiovascular, oncology, human vaccines, medical devices,
diagnostics and consumer health. Handok, founded in 1954, has grown as a joint
venture with Hoechst/Aventis/Sanofi and has established strategic
collaborations in several areas with multiple multinational pharmaceutical
companies. For more information, please visit


Teva Pharmaceutical Industries:
Investor Relations:
Kevin C. Mannix, 215-591-8912
Kristen Frank, 215-591-8908
Tomer Amitai, 972-3-926-7656
Media Relations
Hadar Vismunski-Weinberg, 972-3-926-7275
Denise Bradley, 215-591-8974
Press spacebar to pause and continue. Press esc to stop.